There are currently 1264 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Neuroblastoma
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Local Institution - 001-833 - H, Columbus, Ohio +10 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +4 locations
Conditions: Ovarian Carcinoma
Register for Updates
Academic-Community EPINET (AC-EPINET)
NCT04497857
Recruiting
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
Gender:
ALL
Ages:
Between 16 years and 35 years
Trial Updated:
09/17/2024
Locations: The Early Psychosis Intervention Center (EPICENTER) at Ohio State, Columbus, Ohio
Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Register for Updates
Phase 2 Study of EDG-5506 in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy (FOX)
NCT06100887
Recruiting
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Gender:
MALE
Ages:
Between 6 years and 17 years
Trial Updated:
09/17/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Duchenne Muscular Dystrophy
Register for Updates
The Periviable GOALS Decision Support Tool
NCT05264779
Recruiting
The Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool (DST) is meant to facilitate informed shared decision-making regarding neonatal resuscitation for families facing the threat of a periviable delivery (deliveries occurring between 22 0/7 - 25 6/7 weeks gestational age). It is designed for parents to review independent of their clinician, and is intended to supplement, not replace, clinician counseling. The focus of the DST is the provision of patient-cente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: The Ohio State University, Columbus, Ohio
Conditions: Pregnancy Preterm, Premature Birth, Pregnancy Complications, Obstetric Labor, Premature, Obstetric Labor Complications
Register for Updates
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03013998
Recruiting
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negativ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Ohio State University, Columbus, Ohio
Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Register for Updates
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT06330805
Recruiting
This phase II trial compares the effect of relugolix to leuprolide on cardiac function and performance in patients with prostate cancer. Androgen deprivation therapy (ADT) has been a key component for the treatment of advanced prostate cancer for decades. The term androgen deprivation therapy means lowering a man's testosterone. Long-term studies show that ADT may contribute to a detriment to cardiac health and predisposes men to developing cardiac diseases. Recent studies suggest that men takin... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Register for Updates
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
NCT04730258
Recruiting
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Register for Updates
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT05251714
Recruiting
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Advanced Solid Tumor, Breast Cancer
Register for Updates
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377
Recruiting
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/16/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Sickle Cell Trait
Register for Updates
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05961839
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio
Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Register for Updates